泛素修饰调节肿瘤免疫治疗耐药机制和潜在治疗靶点。
Ubiquitin modification in the regulation of tumor immunotherapy resistance mechanisms and potential therapeutic targets.
发表日期：2024 Aug 30
作者：
Zihang Hong, Furong Liu, Zhanguo Zhang
来源：
Cellular & Molecular Immunology
摘要：
尽管基于免疫检查点的癌症免疫疗法在多种癌症中显示出显着疗效，但耐药性仍然限制了其治疗效果。泛素化修饰是在蛋白质上添加不同类型的泛素链，介导蛋白质降解或改变其功能，从而影响细胞信号转导的机制。越来越多的证据表明，泛素化修饰在调节癌症免疫治疗的耐药机制中发挥着至关重要的作用。针对泛素化修饰途径的药物已被证明可以抑制肿瘤进展或增强癌症免疫治疗的功效。本文详细阐述了肿瘤细胞、免疫细胞和肿瘤微环境介导癌症免疫治疗耐药的机制以及泛素化修饰如何调节这些机制的细节，为通过泛素化修饰干预来增强癌症免疫治疗的疗效提供了基础。 © 2024。作者。
Although immune checkpoint-based cancer immunotherapy has shown significant efficacy in various cancers, resistance still limits its therapeutic effects. Ubiquitination modification is a mechanism that adds different types of ubiquitin chains to proteins, mediating protein degradation or altering their function, thereby affecting cellular signal transduction. Increasing evidence suggests that ubiquitination modification plays a crucial role in regulating the mechanisms of resistance to cancer immunotherapy. Drugs targeting ubiquitination modification pathways have been shown to inhibit tumor progression or enhance the efficacy of cancer immunotherapy. This review elaborates on the mechanisms by which tumor cells, immune cells, and the tumor microenvironment mediate resistance to cancer immunotherapy and the details of how ubiquitination modification regulates these mechanisms, providing a foundation for enhancing the efficacy of cancer immunotherapy by intervening in ubiquitination modification.© 2024. The Author(s).